A Phase Ib/II, Two-part, Non-randomized, Open-label Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Chidamide in Combination With Regorafenib in Patients With Hepatocellular Carcinoma
Latest Information Update: 14 Mar 2025
At a glance
- Drugs Regorafenib (Primary) ; Tucidinostat (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors GNT Biotech and Medicals Corporation
Most Recent Events
- 12 Mar 2025 Status changed from recruiting to discontinued.
- 22 Feb 2024 The protocol has been amended, the study will now recruit patients who are 18 years of age or older.
- 24 Mar 2023 New trial record